| 货号: S221386 |
| 产品全名: SLC8A1 兔多抗 |
| 基因符号 NCX1 |
| UNIPROT ID: P32418 (Gene Accession – NP_066920 ) |
| 背景: In cardiac myocytes, Ca(2+) concentrations alternate between high levels during contraction and low levels during relaxation. The increase in Ca(2+) concentration during contraction is primarily due to release of Ca(2+) from intracellular stores. However, some Ca(2+) also enters the cell through the sarcolemma (plasma membrane). During relaxation, Ca(2+) is sequestered within the intracellular stores. To prevent overloading of intracellular stores, the Ca(2+) that entered across the sarcolemma must be extruded from the cell. The Na(+)-Ca(2+) exchanger is the primary mechanism by which the Ca(2+) is extruded from the cell during relaxation. In the heart, the exchanger may play a key role in digitalis action. The exchanger is the dominant mechanism in returning the cardiac myocyte to its resting state following excitation. |
| 抗原: Synthetic peptide of human SLC8A1 |
| 经过测试的应用: ELISA, IHC |
| 推荐稀释比: IHC: 50-100; ELISA: 5000-10000 |
| 种属反应性: Rabbit |
| 克隆性： Rabbit Polyclonal |
| 亚型: Immunogen-specific rabbit IgG |
| 纯化: Antigen affinity purification |
| 种属反应性: Human, Mouse, Rat |
| 成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol |
| 研究领域: Signal Transduction, Cancer, Cardiovascular, Metabolism |
| 储存和运输: Store at -20°C. Avoid repeated freezing and thawing |
Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 221386(SLC8A1 Antibody) at a dilution of 1/30(Cytoplasm and Cell membrane). | 
In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 221386(Anti-SLC8A1 Antibody) at dilution 1/30. | 
The image on the left is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using 221386(Anti-SLC8A1 Antibody) at a dilution of 1/30. | 
In comparision with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with synthetic peptide and then with D262951(Anti-SLC8A1 Antibody) at dilution 1/30. |
|
